Polatuzumab Vedotin OverviewPolatuzumab vedotin (INN; brand name Polivy, is an antibody-drug conjugate or ADC designed for the treatment of cancer. The US Food and Drug Administration approved polatuzumab vedotin in June 2019 for treatment of diffuse large B-cell lymphoma when used in combination with bendamustine and rituximab. The drug was developed by Genentech and Roche.[not verified in body] History In June 2019, polatuz...
Read more Polatuzumab Vedotin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Polatuzumab_vedotin
Recent Polatuzumab Vedotin Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 140mg
- Powder: 140mg/vial, 30mg/vial
Other drugs which contain Polatuzumab Vedotin or a similar ingredient: (1 result)
- POLIVY Polatuzumab Vedotin-piiq